지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 1998.12
- 수록면
- 223 - 229 (7page)
이용수
초록· 키워드
오류제보하기
Mirtazapine is a Noradrenergic and Specific Serotonergic Antidepressant(NaSSA). It enhances noradrenergic transmission by blocking α₂-adrenergic autoreceptors. In addition, mirtazapine enhances serotonergic transmission via two synergistic mechanisms : an increase of 5-HT cell firing and blockade of α₂-adrenergic heteroreceptors. Mirtazapine specifically enhances 5-HT₁-mediated transmission while 5-HT₂ and 5-HT₃ receptors are blocked by mirtazapine.
Mirtazapine has demonstrated clinical efficacy in the treatment of moderately and severely depressed patients. Mood improvement with mirtazapine is seen within 1 week of treatment, and therapeutic effects are sustained throughout the treatment period. Because of its unique pharmacological profile, mirtazapine is virtually devoid of anticholinergic, adrenolytic, and serotonin-related side effects. The most frequently reported adverse events were transient sedation and weight gain.
The recommended dosing schedule is to start treatment with 15㎎/day for 4 days, followed by 30㎎/day for 10 days. Treatment may continue with the unchanged daily dose(30㎎/day) in patients showing a satisfactory therapeutic response, or it can subsequently be raised to 45㎎/day in patients assessed as not sufficiently improved after 14 days.
Mirtazapine has demonstrated clinical efficacy in the treatment of moderately and severely depressed patients. Mood improvement with mirtazapine is seen within 1 week of treatment, and therapeutic effects are sustained throughout the treatment period. Because of its unique pharmacological profile, mirtazapine is virtually devoid of anticholinergic, adrenolytic, and serotonin-related side effects. The most frequently reported adverse events were transient sedation and weight gain.
The recommended dosing schedule is to start treatment with 15㎎/day for 4 days, followed by 30㎎/day for 10 days. Treatment may continue with the unchanged daily dose(30㎎/day) in patients showing a satisfactory therapeutic response, or it can subsequently be raised to 45㎎/day in patients assessed as not sufficiently improved after 14 days.
목차
영어 초록
서론
1. 작용기전(Modo of action)
2. 약동학(Pharmacokinetics)
3. 임상효과
4. 내약성과 안전성
5. 약물상호작용
6. 용법 및 용량
결론
참고문헌
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Mirtazapine 사용후 정좌불능증(Akathisia)을 보인 환자 3례
생물정신의학
2001 .01
-
The Tolerability of Mirtazapine Augmentation in Schizophrenic Patients Treated with Risperidone: A Preliminary Randomized Placebo-controlled Trial
Clinical Psychopharmacology and Neuroscience
2011 .01
-
A 52-Year-Old Woman Who Experienced a Myocardial Infarction during Treatment for Depression with Mirtazapine
Clinical Psychopharmacology and Neuroscience
2006 .01
-
Comparison of Side Effect Profiles between Mirtazapine and Selective Serotonin ReuptakeInhibitors ; A Naturalistic Setting
Clinical Psychopharmacology and Neuroscience
2004 .01
-
Simplified HPLC Method for the Determination of Mirtazapine in Human Plasma and Its Application to Single-dose Pharmacokinetics
The journal of applied pharmacology : the official journal of the Korean Society of Applied Pharmacology
2006 .01
-
CYP2D6 P34S Polymorphism and Mirtazapine Responses in Koreans with Major Depression
Molecular & cellular toxicology
2009 .01
-
Mirtazapine Augmentation for Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction: A Retropective Investigation
PSYCHIATRY INVESTIGATION
2011 .01
-
Over-Sedation, the Main Toxic Effect of Mirtazapine Overdose?
Clinical Psychopharmacology and Neuroscience
2010 .01
-
A Comparison of Mirtazapine and Paroxetine for the Treatment of Patients with Posttraumatic Stress Disorder: A Randomized Open-label Trial
Clinical Psychopharmacology and Neuroscience
2010 .01
-
Effect of Mirtazapine on MNNG-Induced Gastric Adenocarcinoma in Rats
Asian Pacific journal of cancer prevention : APJCP
2012 .01
-
No Association between Serotonin Receptor 2C-759C/T Polymorphism and Weight Change or Treatment Response to Mirtazapine in Korean Depressive Patients
PSYCHIATRY INVESTIGATION
2013 .01
-
Mirtazapine Is Effective in Steroid Withdrawal Syndrome Related Depression: A Case Report
Clinical Psychopharmacology and Neuroscience
2017 .01
-
R347C Polymorphisms in ADRA1A Genes and Mirtazapine Treatment Response in Koreans with Major Depression
생물정신의학
2015 .01
-
Methylphenidate에 의해서 유발된 주의력결핍-과잉행동장애 환자의 수면장애에 대한 Mirtazapine의 치료효과 : 증례 및 고찰
생물치료정신의학
2006 .12
-
외상후 스트레스 장애 환자에서 Mirtazapine과 Sertraline의 치료효과 및 안정성
신경정신의학
2005 .01
-
βTC-6 세포에서 Floxetine과 Mirtazapine이 인슐린 분비에 미치는 영향
생물치료정신의학
2004 .12
-
Resolution of Pregabalin and Mirtazapine Associated Restless Legs Syndrome by Bupropion in a Patient with Major Depressive Disorder
PSYCHIATRY INVESTIGATION
2009 .01
-
Association between the Alu Insertion/Deletion Polymorphism in the Tissue-Type Plasminogen Activator Gene and Mirtazapine Response in Koreans with Major Depression
생물정신의학
2016 .01
-
Effect of prokinetics on the gastrointestinal transit of a capsule endoscope in healthy 4 beagles
Journal of Biomedical and Translational Research
2019 .01
-
Treatment with Selective Serotonin Reuptake Inhibitors and Mirtapazine Results in Differential Brain Activation by Visual Erotic Stimuli in Patients with Major Depressive Disorder
PSYCHIATRY INVESTIGATION
2009 .01
이 논문의 저자 정보
이 논문과 함께 이용한 논문
핵산유도체들의 항 Human Immunodeficiency Virus in vitro 약효평가와 작용기전연구
이종교
,
김동기
,
김지현
외 4명
JOURNAL OF BACTERIOLOGY AND VIROLOGY
1997
.06
스코폴라민으로 유도된 기억력 손상에 대한 복신의 보호 효과 및 작용기전 연구
제갈경환
,
박성준
,
김창열
외 3명
동의생리병리학회지
2010
.04
악성중피종세포에서 항암제 저항성인자 규명과 작용기전 증명
김성우
,
이용진
,
이상한
외 7명
대한직업환경의학회 학술대회 논문집
2013
.11
루테올린의 간암세포 성장 억제효능 및 새로운 작용기전
황진택
,
양혜정
KSBB Journal
2010
.12
AI 기반 신약개발 기술 현황과 미래
정명희
,
권원현
한국정보통신학회 여성 ICT 학술대회 논문집
2021
.08
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2009-513-017205820